OBJECTIVES Cutaneous Leishmaniasis is a common and endemic disease in Khorasan province in North-East of Iran. The pentavalant antimony (Sb V) is the mainstay of treatment that has many side effects and resistance to the drug has been reported. The microbicidal effect of ozone was proven in different microorganisms. Since there is no study in this respect and to achieve a low cost and effective...

BACKGROUND The histopathology and immune responses of the healing process of leishmaniasis are still poorly studied. OBJECTIVES This study aimed to examine the histopathological and immunological aspects of lesions of patients with cutaneous leishmaniasis before and after different therapeutic methods. METHODS We studied 23 individuals grouped according to the treatments: Glucantime, Glucan...

BACKGROUND Leishmaniases are a group of diseases caused by Leishmania parasites. Growing of drug unresponsiveness in leishmaniasis patients necessitates the development of new drugs and accordingly a suitable assay is needed for evaluation of any modalities. The aim of this study was to compare four drug assays methods, agar dilution, broth dilution, cylinder plate and disk diffusion, for evalu...

background: glucantime ® is the first- line drug for the treatment of all forms of leishmaniasis. unfortunately, the prevalence of parasites becoming resistant to glucantime ® is increasing in several parts of the world including iran. as protein is the most important target for drugs in response to a variety of signals including drugs so, it seems expression protein patterns in sensitive and r...

Cutaneous leishmaniasis (CL) is a serious health challenge at the global level due to Leishmania tropica. This study was conducted to evaluate the risk factors associated with anthroponotic CL (ACL) in unresponsive (patient who does not heal and remains with an active lesion, despite receiving two courses of intra-lesional Glucantime along with cryotherapy and one cycle of systemic Glucantime) ...

BACKGROUND Leishmaniasis is a complex disease which presents as visceral, cutaneous and mucocutaneous forms. The current treatment options for this infection are very limited and the immunological state of the host appears to play an important role in the efficacy of the treatment. Immunostimulation through immune response activating agents such as Imiquimod is another rational approach for thi...

of 1.3 mg/kg for 7 days in combination with 5 (mg/kg)/day of chloroquine. Antileishmanial Test Method. The antileishmanial activity of 2d was determined in golden hamsters by the method of Hanson et Male golden hamsters were inoculated intracardially with lo7 amastigotes of the Khartoum strain of Leishmania donovani. Administration of the drug was begun 3 days after inoculation and was continue...

Leishmaniasis is a neglected and endemic disease that affects poorest population mainly in developing countries. A lack of adequate and definitive chemotherapeutic agents to fight against this infection has led to the investigation of numerous compounds. The aim of this study was to investigate in vitro activity of boldine against Leishmania amazonensis murine cell infection. Boldine ((S)-2,9-d...

Background. Topical treatment of cutaneous leishmaniasis is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. Recently liposomal formulations of amphotericin B have been increasingly used in the treatment of several types of leishmaniasis. Aims. The efficacy of a topical liposomal amphotericin B formulation was compared...

BACKGROUND Leishmaniasis is one of the six most common parasitic infections in the tropical regions. There are different therapeutic modalities, however therapeutic resistance is developed and resulted in numerous problems. Therefore, evaluation of other therapeutic modalities is performed extensively. OBJECTIVES The current study aimed to compare the therapeutic response of cutaneous leishma...